Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Exclusion Criteria

• •Patients with Stage \>IIA CTCL at the time of enrolment
• •Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception
• •Patients who were treated with topical retinoid therapy in the past 3 months
• •Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date
• •Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date